请使用支持JavaScript的浏览器! CellGenix/CellGenix® rh IL-4/1 mg/1003-1000_蚂蚁淘,【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城
商品信息
联系客服
CellGenix/CellGenix® rh IL-4/1 mg/1003-1000
郑重提醒:
无质量问题不接受退换货,下单前请仔细核对信息。
下单后请及时联系客服核对商品价格,订单生效后再付款。
CellGenix/CellGenix® rh IL-4/1 mg/1003-1000
品牌 / 
CellGenix
货号 / 
1003-1000
美元价:
(友情提示:该价格仅为参考,欢迎联系客服询价!)
数    量:
免费咨询热线
4000-520-616

Technical Details

Source
Expressed in E. coli
Description

Human Interleukin-4, accession # P05112, His25-Ser153

Formulation

Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5

Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.

 PreclinicalGMP
Molecular weight15.1 kDa15.1 kDa
Purity≥ 95% as determined by SDS-PAGE≥ 97% as determined by SDS-PAGE
Activity≥ 6 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF18 – 14 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF1

Batch specific activity on CoA

Endotoxin level< 1000 EU/mg≤ 50 EU/mg
Intended useIntended for preclinical ex vivo use. Not intended for therapeutic use.Intended for clinical ex vivo use. Not intended for human in vivo application.

Handling Instructions

Reconstitution

Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials or 500 µg/ml for 1 mg vials.

Shipment

Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.

Expiry

≥ 6 months from date of shipping. Please refer to Certificate of Analysis for the exact expiry date.

Storage & Stability

Store lyophilized cytokine at -20°C to -80°C.

Store a 250 µg/ml reconstituted cytokine solution:

• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container. 

• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.

Avoid repeated freeze/thaw cycles.

Documents

  • Data Sheet: GMP or Preclinical
  • Material Safety Data Sheet: MSDS
  • Certificate of Analysis
  • Technote: ADCF and Serum-free Policy
  • Technote: Batch-to-Batch Consistency of CellGenix® GMP Cytokines
  • Technote: Stability of CellGenix® GMP Cytokines after Reconstitution
  • Technote: Shipment of CellGenix® Preclinical and GMP Cytokines at Ambient Temperatures
  • Technote: CellGenix® rh Cytokines - Preclinical vs GMP
  • More information under Resources

Data

CellGenix GMP rh IL-4 has an activity of 8 – 14 × 106 IU/mg

The activity of GMP rh IL-4 was measured in a cell proliferation assay using the IL-4-dependent cell line TF1. It was calibrated against NIBSC #88/656.

You can find the batch specific activity on the certificate of analysis (CoA).

Regulatory Support

We offer the following to assist you with your regulatory approval process:

  • Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
  • Outstanding QC support (e.g. extensive stability data)
  • The possibility to audit our production site
  • Detailed batch specific test results on our Certificates of Analysis
  • Change notifications prior to relevant changes

Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:

Phone:     +49 761 88 88 9-302 Email:      regulatorysupport@cellgenix.com

In order to stay up-to-date and help improve regulatory guidance we are actively involved in many of the regulatory initiatives and discussions. We were amongst others actively involved in the discussions for the setup of Ph. Eur. General Chapter 5.2.12 and the ISO Technical Standard 20399.

Regulatory Resources

  • TSE certificate (available on request)
  • Regulatory Support File (available on request)
  • Request a DMF Letter of Authorization (USA only)

Publications

  • The importance of material selection in the differentiation of monocytes into dendritic cellsBoghosian et al., 2018, Cell & Gene Therapy Insights
  • Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritisBell, GM. Et al., 2017, Annals of the Rheumatic Diseases
  • Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21Hansen, M. et al., 2016, Cytotherapy
  • Tumor antigen–specific T cells for immune monitoring of dendritic cell–treated glioblastoma patientsMüller, I. et al., 2016, Cytotherapy
  • Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate CancerXi, HB. et al., 2015, Biological & Pharmaceutical Bulletin
  • Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell deathVogel, S. et al., 2015, Cell Death and Differentiation
  • NF-kB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environmentDá?ová, K. et al., 2015, Oncotarget
  • Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantationSundarasetty, BS. et al., 2015, Journal of Translational Medicine
  • Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patientsGao, D. et al., 2014, PLoS One
  • A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaPoschke, I. et al., 2014, Cancer Immunology, Immunotherapy
  • Antigen-specific activation and cytokine-faciliated expansion of naive, human CD8+ T cellsWölfl, M., Greenberg, PD., 2014, Nature Protocols
  • TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIFKolanowski, ST. et al., 2014, Innate Immunity
  • Inhibition of TNF receptor signaling by anti-TNF-a biologicals primes naive CD4+ T cells towards IL-10+ T cells with a regulatory phenotype and functionBooks, MA. et al., 2014, Clinical Immunology
  • In-chip fabrication of free-form 3D constructs for directed cell migration analysisOlsen, MH. et al., 2013, Lab on a Chip
  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesPellegatta, S. et al., 2013, Oncoimmunology
  • Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyHansen, M. et al., 2013, Vaccine
  • Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancerIclozan, C. et al., 2013, Cancer Immunology, Immunotherapy
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeDanull, J. et al., 2013, The Journal of Clinical Investigation
  • Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine produtionZaal, A. et al., 2013, Immunobiology
  • Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsRidolfi, L. et al., 2013, Journal of Translational Medicine
  • The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cellsSorvillo, N. et al., 2012, Blood
  • Myeloid-derived suppressor cells impair the quality of dendritic cell vaccinesPoschke, I. et al., 2012, Cancer Immunology, Immunotherapy
  • Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A miceWroblewska, A. et al., 2012, Blood
  • Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor CellsLazarova, P. et al., 2012, Immunodeficiency, Chapter 3
  • Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapyVopenkova, K. et al., 2012, Journal of Cellular and Molecular Medicine
  • Identitiy, potency in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapyPincha, M. et al., 2012, Human Gene Therapy Methods
  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastomaNava, S. et al., 2012, PloS One
  • A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaChia, WK. et al., 2012, Annals of Oncology
  • Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical useGülen, D. et al., 2012, International Immunopharmacology
  • IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction – a comparative study of human clinical-applicable DCBoks, MA. et al., 2012, Clinical Immunology
  • HLA-DR-presented peptide-repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIIIvan Haren, SD. et al., 2011, Molecular & Cellular Proteomics
  • Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitroEtminan, N. et al., 2011, British Journal of Cancer
  • Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolizationNakamato, Y. et al., 2011, Clinical and Experimental Immunology
  • Antigen-Specific B Cells Reactivate an Effective Cytotoxic T Cell Response against Phagocytosed Salmonella through Cross-Presentationde Wit, J. et al., 2010, PLoS One
  • Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcomeVenanzi, FM. et al., 2010, Cancer, Immunology, Immunotherapy
  • A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oyaliplatin/capecitabine chemotherapy in colon cancer patientsLesterhuis, WJ. et al., 2010, British Journal of Cancer
  • Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis)Ridolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cellsTraxlmayr, MW. et al., 2010, Journal of Immunotherapy
  • Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patientsLesterhuis, WJ. et al., 2010, Anticancer Research
  • Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcomeRidolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Autologous dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteersLuo, J. et al., 2010, Vaccine
  • Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trialTrepiakas, R. et al., 2010, Cytotherapy
  • CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signalsSender, LY. et al., 2010, Molecular Immunology
  • Monophosphoryl lipid A plus IFN gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic cells with high cytolytic potentialten Brinke, A. et al., 2010, Cancer Immunology, Immunotherapy
  • Development of a potency assay for human dendritic cells: IL-12p70 productionButterfield, LH. et al., 2008, Journal of Immunotherapy
蚂蚁淘电商平台
ebiomall.com
公司介绍
公司简介
蚂蚁淘(www.ebiomall.cn)是中国大陆目前唯一的生物医疗科研用品B2B跨境交易平台, 该平台由多位经验丰富的生物人和IT人负责运营。蚂蚁淘B2B模式是指客户有采购意向后在蚂蚁 淘搜索全球供应信息,找到合适的产品后在蚂蚁淘下单,然后蚂蚁淘的海外买手进行跨境采购、 运输到中国口岸,最后由蚂蚁淘国内团队报关运输给客户...
蚂蚁淘承诺
正品保证: 全球直采 在线追溯 蚂蚁淘所有产品都是自运营的,我们已经跟国外多家厂方建立品牌推广合作关系, 获得对方的支持和授权; 同时客户可以通过订单详情查看到货物从厂方至客户的所有流程, 确保货物的来源; 正规报关,提供13%增值税发票。
及时交付: 限时必达 畅选无忧 蚂蚁淘的运营团队都是有着多年经验的成员,他们熟悉海外采购、仓储物流、报关等环节; 同时通过在线的流程监控,蚂蚁淘的进口速度比传统企业提高了50%以上, 部分产品甚至能做到7-10天到货,即蚂蚁淘的“时必达”服务。
轻松采购: 在线下单 简单省事 蚂蚁淘的价格是真实透明的,并且具有很大的价格优势,不需要繁杂的询价比价; 报价单与合同可以直接在线生成或打印;就像在京东购物一样, 您的鼠标点击几 次即完成在蚂蚁淘的采购,订单详情会告诉您所有进程。
售后申请: 耐心讲解 优质服务 蚂蚁淘提供的产品在使用过程中如因产品质量问题有售后需求时, 您可通过我的订单提交您的“申请售后”, 蚂蚁淘产品顾问会第一时间为您处理, 在售后服务过程中如遇到问题也可致电蚂蚁淘客服热线:4000-520-616。
磷酸盐缓冲液(Phosphate Buffered Saline,简称PBS)的是常用的用于生物学研究的一个缓冲溶液。... 查看更多>
上海博升生物科技有限公司在发布的Medicago 硼酸盐缓冲液和重碳酸盐缓冲液片剂供应信息,浏览与Medicago 硼酸盐缓冲液和重碳酸盐缓冲液片剂相关的产品或在搜索更多与Medicago 硼酸盐缓冲液和重碳酸盐缓冲液片剂相关的内容。 查看更多>
南京科佰生物科技有限公司在发布的天根Tiangen现货洗脱缓冲液TE货号:RK121-02供应信息,浏览与天根Tiangen现货洗脱缓冲液TE货号:RK121-02相关的产品或在搜索更多与天根Tiangen现货洗脱缓冲液TE货号:RK121-02相关的内容。 查看更多>
上海远慕生物科技公司是国内elisa试剂盒供应商,代理销售不同elisa试剂盒品牌的进口/国产elisa试剂盒,专业供应科研实验所需的培养基,抗体,动物血清血浆,标准品对照品,化学试剂,酶联免疫试剂盒,白介素试剂盒,金标检测试剂盒,微生物,蛋白质,ELISA种属涵盖广,凭借多年行业经验,完善的售后服务,高质量的产品。咨询。 客户通过中国安防展览网成功订购远慕染色液/缓冲液,下面是跟客户的聊天记录: 常用缓冲液配制 枸橼酸-磷酸氢二钠 ... 查看更多>
常州启航生物科技有限公司在发布的BlockPRO 无蛋白封闭缓冲液 (BlockPRO Protein-Free Blocking Buffer)供应信息,浏览与BlockPRO 无蛋白封闭缓冲液 (BlockPRO Protein-Free Blocking Buffer)相关的产品或在搜索更多与BlockPRO 无蛋白封闭缓冲液 (BlockPRO Protein-Free Blocking Buffer)相关的内容。 查看更多>
规格(核心参数):500ml/瓶;PH6.86;是PH计/酸度计上面用的试剂,也叫标准缓冲溶液 查看更多>
上海研生实业有限公司所提供的pH7.0 氯化钠-蛋白胨缓冲液质量可靠、规格齐全,上海研生实业有限公司不仅具有精湛的技术水平,更有良好的售后服务和优质的解决方案,欢迎您来电咨询此产品具体参数及价格等详细信息! 查看更多>
苏州艾莱萨生物科技有限公司在发布的10×电泳转移缓冲液(转膜液)供应信息,浏览与10×电泳转移缓冲液(转膜液)相关的产品或在搜索更多与10×电泳转移缓冲液(转膜液)相关的内容。 查看更多>
青岛高科技工业园海博生物技术有限公司在发布的PH6.8磷酸盐缓冲液供应信息,浏览与PH6.8磷酸盐缓冲液相关的产品或在搜索更多与PH6.8磷酸盐缓冲液相关的内容。 查看更多>
北京生东科技有限公司在发布的柠檬酸钠(0.04mol/L):NaCl(0.02mol/L)缓冲液(pH6.0)SDKJ-R00519-500ml供应信息,浏览与柠檬酸钠(0.04mol/L):NaCl(0.02mol/L)缓冲液(pH6.0)SDKJ-R00519-500ml相关的产品或在搜索更多与柠檬酸钠(0.04mol/L):NaCl(0.02mol/L)缓冲液(pH6.0)SDKJ-R00519-500ml相关的内容。 查看更多>
常见问题
蚂蚁淘所售产品均为正品吗?
蚂蚁淘的创始人兼CEO是钟定松先生,具有十年的从业经验,在业界享有良好的口碑; Ebiomall是跨境直采平台,我们直接从厂家采购,自己的团队负责国际物流和清关,中间没有第三方,蚂蚁淘承诺所售产品仅为正品,假一罚十。
下单后可以修改订单吗?
未确认状态的订单可以修改,打开“订单详情”页面,点击右上角的“修改订单”即可,若已审核确定,则订单无法修改。
商品几天可以发货?
现货产品付款审核后即可发货,大部分期货产品在3周左右即可到货,提供时必达服务的产品订单审核十天内即可发货。
订单如何取消?
如订单处于未确定状态,进入“我的订单"页面,找到要取消的订单,点击“取消订单”按钮。
可以开发票吗?
本网站所售商品都是正规清关,均开具13%正规发票,发票金额含配送费金额,另有说明的除外。
如何联系商家?
蚂蚁淘任何页面都有在线咨询功能,点击“联系客服”、“咨询”或“在线咨询”按钮,均可咨询蚂蚁淘在线客服人员, 或拨打4000-520-616,除此之外客户可在 联系我们页面找到更多的联系方式。
收到的商品少了/发错了怎么办?
同个订单购买多个商品可能会分为一个以上包裹发出,可能不会同时送达,建议查看订单详情是否是部分发货状态;如未收到,可联系在线客服或者致电4000-520-616。
退换货/维修需要多长时间?
一般情况下,退货处理周期为客户收到产品一个月内(以快递公司显示签收时间为准),包装规格、数量、品种不符,外观毁损、短缺或缺陷,请在收到货24小时内申请退换货;特殊商品以合同条款为准。
商品咨询
缓冲液;能抵御少量的酸,碱或稀释少量倍数时,体系的pH基本不变的溶液称为缓冲溶液.缓冲溶液的缓冲对一般是由共轭酸碱对或两性物质组成.缓冲对在生物中是指酸碱性相反的东西,,可以相互中和,比如在人体中,乳酸和碳酸氢钠就是一对缓冲对
求采纳为满意回答。
McIlvaine缓冲液 123
jop975642017-10-03
McIlvaine缓冲液属于广域缓冲溶液,pH调节范围在3~8之间,缓冲范围较大,可以用于多种用途,例如线粒体的分离染色等。Leagene的McIlvaine缓冲液(pH4.1)主要由磷酸氢二钠和柠檬酸组成,pH4.1,属于最常用的一种广域缓冲溶液。

WB前,上样缓冲液是买的成品,在-20°冰箱保存,之前做一直正常,这次蛋白样品加上样缓冲液后变成棕色了?啥情况?是蛋白样品PH值的关系吗?这个还能继续跑电泳吗?

哪位高手给指导一下,谢谢!

日本药典中0.1mol/L的磷酸缓冲液pH7.0是怎么配置的啊,求救!!!!

凝胶过滤中的脱盐柱的使用123
山东圣奥LL2021-07-21

样品是血液,想要从血清中提纯一种蛋白,实验设计是过两个柱子,DEAE-FF预装柱+S-SepharoseFF预装柱,两个柱子都是20ml,上样量5ml的柱子……做实验过程发现样品的浓缩是一个大麻烦事情,还有一个就是过第二个柱子之前对样品的处理(置换缓冲溶液+浓缩),实验室有GE的HitrapDesalting脱盐柱,5ml的,想请教一下各位前辈,怎么使用脱盐柱进行缓冲液的置换?具体怎么步骤??谢谢…………


TBS缓冲液 123
弘贝方弘2017-10-02
索莱宝的TBS缓冲液怎么样

小白用SF9表达了一个磷酸化蛋白,用his纯化,不小心用了PBS做缓冲液,质谱检测出了一个别人没有发现的磷酸化位点,后面发现自己用的是磷酸盐溶液,小白想知道

磷酸盐缓冲液对于磷酸化蛋白检测的影响,会改变或影响磷酸化蛋白的修饰吗?

浓度为0.11mol/l及pH7.2的磷酸盐缓冲液怎么配制?

像图中所示,我1%的羧基微球用EDC活化,离心后用50Mm、PH7.2的PB缓冲液悬浮,用超声波超声5分钟,然后就分层了,上层是微球。

TE缓冲液(pH 8.0)配制方法 123
风记社六团mfj2017-09-28
10 mmol/LTris-HCl(pH 8.0)
  1 mmol/LEDTA(pH 8.0)
  因为含有以上两种物质,所以称为TE。
  配制分三步:
  1)1 M Tris-HCl (pH 8.0) 50 ml的配制:称取Tris碱6.06 g,加超纯水40 ml溶解,滴加浓HCl约2.1 ml调pH至8.0,定容至50 ml。
  2)0.5 M EDTA(pH 8.0)50 ml的配制:称取EDTA-Na2·2H2O 9.306 g,加超纯水35 ml,剧烈搅拌,用约1 g NaOH颗粒调pH至8.0,定容至50 ml。(EDTA二钠盐需加入NaOH将pH调至接近8.0时,才会溶解。)
  3)1×TE(10 mM Tris-HCl,pH 8.0;1 mM EDTA,pH 8.0)的配制:
  作用:
  TE缓冲液是弱碱性,对DNA的碱基有保护性,(DNA在它是的稳定性较好,不易破坏其完整性或产生开环及断裂),包括提取好的DNA也要放在TE缓冲液是保存. 10mMTris-Hcl,pH有7.47.68.0三种。
  EDTA调到8.0是为了更好溶解,其他只要调到相应pH就可以。Tris在7-8附近缓冲能力很强,所以加8.0的EDTA下去后,不会改变pH。
中间一个小圈是什么情况?求大神解答

1、组成成分:

A、1×TE缓冲液:10mmol/LTris.Cl;1mmol/LEDTA,pH8.0。

B、1×TAE缓冲液:40mmol/LTris-乙酸;2mmol/LEDTA,pH8.0。

C、1×TBE缓冲液:45mmol/LTris-硼酸;1mmol/LEDTA,pH8.0。

2、用途:

A、TE缓冲液:一般用作溶解剂或保持剂,常用于溶解DNA,能稳定储存DNA。

B、TAE缓冲液:生物学中使用最广泛的核酸电泳缓冲液,主要用于DNA的琼脂糖凝胶电泳。

C、TBE缓冲液:生物学中常用的核酸电泳缓冲液,主要用于DNA的琼脂糖凝胶电泳。

3、TAE和TBE缓冲液的选择:

TAE和TBE缓冲液都可以用于DNA的琼脂糖凝胶电泳,两者各有利弊,应根据实际情况选择不同的缓冲液。

4、注意:

TBE浓溶液长时间存放后会形成沉淀物,出现沉淀后应予以废弃。